MACROGENICS INC
No SEC Form 4 filings for $MGNX in the last 30 days.
See all $MGNX insider activity →MacroGenics (NASDAQ:MGNX) shares rose 4.3% after hours after Gilead Sciences exercised an option on a preclinical bispecific program under their 2022 collaboration, triggering a $10 million payment. Gilead holds an exclusive license using MacroGenics’ TRIDENT platform targeting two undisclosed solid tumor targets. MacroGenics may receive up to about $1.6 billion more in milestones and royalties.
MACROGENICS INC (MGNX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. mgnx-20260701 0001125345 FALSE 0001125345 2026-07-01 2026-07-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):
MACROGENICS INC (MGNX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.2 3 exhibit99-2proforma.htm EX-99.2 Document Exhibit 99.2 MACROGENICS, INC. UNAUDITED CONSOLIDATED PRO FORMA FINANCIAL INFORMATION Effective as of June 30, 2026, MacroGenics, Inc. (the “Company”) completed the previously announced sale (the “Closing”) of certain assets and
Over the past 7 days, alphai's AI scored 1 news story mentioning MGNX (MACROGENICS INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent MGNX coverage spans mergers & acquisitions, financial news and corporate actions.
The $10M option-exercise payment is a near-term cash inflow and de-risks continued collaboration activity, supporting sentiment for MGNX.
Board change is a governance/catalyst item, but the filing provides no operational dispute or business change.
Asset sale reduces/reshapes MacroGenics’ manufacturing footprint and alters revenue/cost mix via removal of contract manufacturing and related costs.
The $24.5M milestone entitlement is a tangible cash-flow catalyst tied to Sanofi’s regulatory milestone event.
The transaction is a portfolio/asset sale that may reduce manufacturing footprint while creating ongoing CDMO-related economics via the service agreement.
alphai scores every news story that mentions MGNX with an AI model for sentiment and relevance, and aggregates insider trades from MACROGENICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
MacroGenics (NASDAQ:MGNX) shares rose 4.3% after hours after Gilead Sciences exercised an option on a preclinical bispecific program under their 2022 collaboration, triggering a $10 million payment. Gilead holds an exclusive license using MacroGenics’ TRIDENT platform targeting two undisclosed solid tumor targets. MacroGenics may receive up to about $1.6 billion more in milestones and royalties.
2 min readMACROGENICS INC (MGNX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. mgnx-20260701 0001125345 FALSE 0001125345 2026-07-01 2026-07-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):
2 min readMACROGENICS INC (MGNX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.2 3 exhibit99-2proforma.htm EX-99.2 Document Exhibit 99.2 MACROGENICS, INC. UNAUDITED CONSOLIDATED PRO FORMA FINANCIAL INFORMATION Effective as of June 30, 2026, MacroGenics, Inc. (the “Company”) completed the previously announced sale (the “Closing”) of certain assets and
4 min readSanofi SA (SNY) said it will appoint Paulo Fontoura as EVP and Global Head of R&D Pharma effective Sept. 1, reporting to CEO Belen Garijo and succeeding Houman Ashrafian. Separately, MacroGenics said it is entitled to $24.5M in regulatory milestone payments from Sanofi after FDA accelerated approval of TZIELD (teplizumab) for children.
4 min readBora Pharmaceuticals (TWSE:6472; OTCQX:BORAY) said it completed its acquisition of MacroGenics’ Rockville, Maryland GMP biologics drug-substance facility and a Frederick warehousing center for $122.5m via Bora Biologics USA. Bora also signed a long-term CDMO service agreement with MacroGenics. Bora Biologics now has 20,000L SUB capacity across US sites and Taiwan.
3 min readBora Pharmaceuticals (TWSE:6472; OTCQX:BORAY) said it completed its acquisition of MacroGenics’ GMP biologics drug-substance manufacturing operations in Rockville, MD, plus a Frederick, MD warehousing center, for $122.5M via Bora Biologics USA. Bora also signed a long-term CDMO service agreement with MacroGenics and now has 20,000L US SUB capacity across Rockville and San Diego.
5 min readMacroGenics (NASDAQ: MGNX) and Bora Pharmaceuticals (TWSE: 6472; OTCQX: BORAY) said the sale of MacroGenics’ GMP drug substance manufacturing operations to Bora has closed. Bora paid $122.5 million (before fees/expenses and post-closing adjustments). Bora assumed responsibility for Rockville, MD and Frederick, MD operations and hired about 140 employees; a supply agreement covers process development and drug substance production for MacroGenics’ pipeline needs.
4 min readMacroGenics (MGNX) drew renewed analyst attention after its Q4 update, with price targets raised by about $1–$2; Barclays lifted its target to $4 from $3, and B. Riley upgraded to Buy after the Tubulus deal. The FDA removed a partial clinical hold on the Phase 2 LINNET lorigerlimab study, allowing new enrollments. Simply Wall St kept fair value at $6.75.
5 min readB. Riley Securities has upgraded Macrogenics (MGNX) from Neutral to Buy, significantly increasing its price target from $3.00 to $9.00, suggesting a 200% growth potential. This upgrade reflects a shifting positive sentiment for the clinical-stage biopharmaceutical company, which focuses on developing antibody-based therapeutics for cancer using various modalities. Despite the upgrade, the average analyst price target for MGNX is $4.00, with a consensus "Hold" status from seven brokerage firms.
4 min readMacroGenics Inc. announced that the U.S. FDA has lifted a partial clinical hold on its Phase 2 LINNET study for lorigerlimab in gynecologic cancers, allowing for the enrollment of new participants under a revised protocol. This decision has been met with investor optimism, reflected in the stock's recent surge. The company anticipates providing a mid-year clinical update on the program.
2 min read
